» Articles » PMID: 28540165

Nanotechnology-based Strategies for Treatment of Ocular Disease

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2017 May 26
PMID 28540165
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

Ocular diseases include various anterior and posterior segment diseases. Due to the unique anatomy and physiology of the eye, efficient ocular drug delivery is a great challenge to researchers and pharmacologists. Although there are conventional noninvasive and invasive treatments, such as eye drops, injections and implants, the current treatments either suffer from low bioavailability or severe adverse ocular effects. Alternatively, the emerging nanoscience and nanotechnology are playing an important role in the development of novel strategies for ocular disease therapy. Various active molecules have been designed to associate with nanocarriers to overcome ocular barriers and intimately interact with specific ocular tissues. In this review, we highlight the recent attempts of nanotechnology-based systems for imaging and treating ocular diseases, such as corneal d iseases, glaucoma, retina diseases, and choroid diseases. Although additional work remains, the progress described herein may pave the way to new, highly effective and important ocular nanomedicines.

Citing Articles

Recent Nanotechnological Trends in the Management of Microbial Keratitis.

Jaiswal S, Shinde P, Tale V J Ophthalmic Vis Res. 2025; 19(4):476-487.

PMID: 39917459 PMC: 11795005. DOI: 10.18502/jovr.v19i4.14498.


Drug delivery strategies to improve the treatment of corneal disorders.

Tafti M, Fayyaz Z, Aghamollaei H, Jadidi K, Faghihi S Heliyon. 2025; 11(2):e41881.

PMID: 39897787 PMC: 11783021. DOI: 10.1016/j.heliyon.2025.e41881.


Correlation of precisely fabricated geometric characteristics of DNA-origami nanostructures with their cellular entry in human lens epithelial cells.

Guo Y, Xiong T, Yan H, Zhang R Discov Nano. 2025; 20(1):13.

PMID: 39841331 PMC: 11754578. DOI: 10.1186/s11671-025-04188-9.


Advancements and Prospects in Nanorobotic Applications for Ophthalmic Therapy.

Menezes Ferreira A, da Silva Felix J, Chaves de Lima R, Martins de Souza M, Sousa Dos Santos J ACS Biomater Sci Eng. 2025; 11(2):958-980.

PMID: 39818739 PMC: 11815637. DOI: 10.1021/acsbiomaterials.4c02368.


Efficacy of Perfluorohexyloctane for the Treatment of Patients with Dry Eye Disease: A Meta-Analysis.

Taloni A, Coco G, Pellegrini M, Scorcia V, Giannaccare G Ophthalmic Res. 2024; 68(1):41-51.

PMID: 39622217 PMC: 11844700. DOI: 10.1159/000542149.


References
1.
Mun E, Morrison P, Williams A, Khutoryanskiy V . On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein. Mol Pharm. 2014; 11(10):3556-64. DOI: 10.1021/mp500332m. View

2.
Pascolini D, Mariotti S . Global estimates of visual impairment: 2010. Br J Ophthalmol. 2011; 96(5):614-8. DOI: 10.1136/bjophthalmol-2011-300539. View

3.
Amrite A, Kompella U . Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005; 57(12):1555-63. DOI: 10.1211/jpp.57.12.0005. View

4.
Mitra M, Kandalam M, Rangasamy J, Shankar B, Maheswari U, Swaminathan S . Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells. Mol Vis. 2013; 19:1029-38. PMC: 3654846. View

5.
Schoenfeld E, Greene J, Wu S, Leske M . Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. Ophthalmology. 2001; 108(3):563-71. DOI: 10.1016/s0161-6420(00)00600-x. View